By Fineline Cube 
Chengdu-based Easton Pharmaceutical Co., Ltd. (SHA: 688513) announced that its oxazepam has received marketing approval from China’s National Medical Products Administration (NMPA). This milestone paves the way for the commercialization of oxazepam in China. In a strategic move, Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), a compatriot firm, has entered into an exclusive commercialization agreement with Easton Pharma. This partnership aims to leverage Nhwa Pharma’s established commercial platform and distribution network to accelerate the market penetration and clinical adoption of oxazepam.
Oxazepam’s Therapeutic Profile
Oxazepam, a short-acting benzodiazepine, is indicated for short-term relief of anxiety, tension, agitation, hypnotic use, adjunctive therapy for anxiety-associated depressive symptoms, and management of acute alcohol withdrawal symptoms. It stands out from traditional anxiolytics with its rapid onset of action, favorable safety profile, and lower risk of dependence, making it ideal for short-term treatment.
Market Context
According to NMPA records, only three domestic manufacturers currently hold approval for oxazepam tablets in China: Beijing Yimin Pharmaceutical Co. Ltd., Hunan Dongting Pharmaceutical Co. Ltd., and now Easton Pharma. Among these, Hunan Dongting and Easton Pharma have passed the generic quality consistency evaluation for their respective versions of the drug.-Fineline Info & Tech